Background Angiotensin-converting enzyme inhibitors (ACE-I) have been widely used for cardiac patients. This study investigated the effect of omitting ACE-I medication on hemodynamics during induction of anaesthesia and operation in patients chronically treated with ACE-I undergoing off pump coronary artery bypass graft surgery (OPCAB). Methods Sixty patients scheduled for OPCAB were included in this study. Patients not treated with ACE-I were included in control group (Group 1, n = 20). And then, patients treated with ACE-I more than 4 weeks were randomly divided into two groups: continuing group including patients who continued ACE-I medication until the morning of surgery (Group 2, n = 20) and discontinuing group including patients who ...
BACKGROUND: Coronary artery bypass grafting (CABG) remains the revascularization treatment of choice...
BACKGROUND: Coronary artery bypass grafting (CABG) remains the revascularization treatment of choice...
The effects of angiotensin-converting enzyme (ACE) inhibition and angiotensin II type 1 receptor blo...
The effects of pre-operative angiotensin-converting enzyme inhibitor (ACEI) treatment on haemodynami...
Despite proven benefit in ambulatory patients with ischemic heart disease, the pattern of use of ang...
Objectives Coronary artery bypass graft surgery may result in perioperative myocardial injury during...
ObjectivesThis study evaluates the effect of pre-operative angiotensin-converting enzyme inhibitor (...
Background-Early after coronary artery bypass surgery (CABG), activation of numerous neurohumoral an...
SummaryBackground and objectivesThe discontinuation of drugs such as angiotensin-converting enzyme i...
Background-Despite proven benefit in ambulatory patients with ischemic heart disease, the pattern of...
<p><strong><em>Background: </em></strong><em>There is controversy over the potential benefits/harms ...
Based on these reports the omission of ACE inhibitors or angiotensin II receptor antagonists before ...
Background: Patients presenting for cardiac surgery are often treated with angiotensin converting en...
Background—Increased plasminogen activator inhibitor-1 (PAI-1) concentrations after coronary artery ...
2011 ACCF/AHA Guidelines for CABG: Uncertain about the safety of the preoperative administration of ...
BACKGROUND: Coronary artery bypass grafting (CABG) remains the revascularization treatment of choice...
BACKGROUND: Coronary artery bypass grafting (CABG) remains the revascularization treatment of choice...
The effects of angiotensin-converting enzyme (ACE) inhibition and angiotensin II type 1 receptor blo...
The effects of pre-operative angiotensin-converting enzyme inhibitor (ACEI) treatment on haemodynami...
Despite proven benefit in ambulatory patients with ischemic heart disease, the pattern of use of ang...
Objectives Coronary artery bypass graft surgery may result in perioperative myocardial injury during...
ObjectivesThis study evaluates the effect of pre-operative angiotensin-converting enzyme inhibitor (...
Background-Early after coronary artery bypass surgery (CABG), activation of numerous neurohumoral an...
SummaryBackground and objectivesThe discontinuation of drugs such as angiotensin-converting enzyme i...
Background-Despite proven benefit in ambulatory patients with ischemic heart disease, the pattern of...
<p><strong><em>Background: </em></strong><em>There is controversy over the potential benefits/harms ...
Based on these reports the omission of ACE inhibitors or angiotensin II receptor antagonists before ...
Background: Patients presenting for cardiac surgery are often treated with angiotensin converting en...
Background—Increased plasminogen activator inhibitor-1 (PAI-1) concentrations after coronary artery ...
2011 ACCF/AHA Guidelines for CABG: Uncertain about the safety of the preoperative administration of ...
BACKGROUND: Coronary artery bypass grafting (CABG) remains the revascularization treatment of choice...
BACKGROUND: Coronary artery bypass grafting (CABG) remains the revascularization treatment of choice...
The effects of angiotensin-converting enzyme (ACE) inhibition and angiotensin II type 1 receptor blo...